Jubilant Pharmova

Amroha, India Founded: 2020 • Age: 6 yrs Listed Fortune India 500 · #334
CDMO focused on manufacturing of solid, semi solid, liquid, and injectible drug formulations

About Jubilant Pharmova

Jubilant Pharmova is a publicly listed company based in Amroha (India) founded in 2020. CDMO focused on manufacturing of solid, semi solid, liquid, and injectible drug formulations. The company has 165 employees. Its chief executive, as recorded, is Jaidev Rajpal. Its Indian entity Jubilant Pharmova Limited reported revenue of ₹8,346 Cr. Its focus areas include Biopharma Outsourcing, CDMO, Small Molecules & Peptides and Formulation. Similar companies include Akums, Jubilant Life Sciences and Nectar Lifesciences; 2 of its 3 listed similar companies have raised funding.

Company details

Jubilant Pharmova was founded in 2020 in Amroha, India, within the pharmaceutical sector. Operations are centered on contract development and manufacturing services for solid, semi-solid, liquid, and injectable drug formulations. The company is headquartered in India, with its domain registered as jubilantpharmova.com. Leadership is provided by CEO Jaidev Rajpal, overseeing production activities for pharmaceutical clients.

Jubilant Pharmova is ranked #334 on the Fortune India 500 (2025).

Recognitions & Rankings of Jubilant Pharmova

Fortune India 500 2025 edition
Rank#334
Total income
₹7,616 Cr
Profit
₹839 Cr
Last year #331
India's Most Valuable Companies 2024 edition · Source: Hurun India
Rank#299
Valuation
₹18,570 Cr
2021 #332
Key Metrics
  • Market Cap
    ₹14,867 Cr

    JUBLPHARMA · NSE

  • Share Price
    ₹935.05

    +0.19% today

  • Revenue
    ₹8,280 Cr

    FY 2025-26 · +14.5% YoY

  • EBITDA
    ₹1,200 Cr

    Margin 14.5%

  • Net Profit
    ₹436 Cr

    FY 2025-26 · +9.1% YoY

  • P/E (TTM)
    50.4x

    P/B 2.1x

  • ROE
    6.0%

    ROCE 6.9%

  • Debt / Equity
    0.48

    Interest cover 27.9x

  • Employee Count
    165

Apps and channels of Jubilant Pharmova

its YouTube channel Jubilant Pharmova has 285 subscribers and 20 videos.

Jubilant Pharmova
YouTube 285 subscribers 20 videos Science & Technology
Open channel

Videos from Jubilant Pharmova

The most watched videos on Jubilant Pharmova's YouTube channel, Jubilant Pharmova (285 subscribers). Click a video to play it here.

Jubilant Life Sciences
11.5K views
Jubilant Employees Speak - Episode 1
1.1K views
Jubilant Employees Speak - Episode 3
745 views
Jubilant Employees Speak - Episode 4
268 views

More on Jubilant Pharmova.

Board of directors of Jubilant Pharmova Limited (Jubilant Pharmova)

Jubilant Pharmova Limited is the primary company behind Jubilant Pharmova. The boards of the 2 registered companies of Jubilant Pharmova currently have 14 directors; the longest-serving is Shyam Sunder Bhartia, appointed in 1978. 52 earlier directors have ceased.

DirectorDesignationAppointedTenureEntity
Shyam Sunder Bhartia
DIN 00010484
Director21 Jun 197848 yrs 5 moJubilant Pharmova Limited
Hari Shanker Bhartia
DIN 00010499
Director01 Nov 198343 yrsJubilant Pharmova Limited
Priyavrat Bhartia
DIN 00020603
Managing Director23 May 20179 yrs 5 moJubilant Pharmova Limited
Arjun Shanker Bhartia
DIN 03019690
Managing Director23 May 20179 yrs 5 moJubilant Pharmova Limited
Vivek Mehra
DIN 00101328
Director23 May 20179 yrs 5 moJubilant Pharmova Limited
Sushil Kumar Roongta
DIN 00309302
Director23 May 20179 yrs 5 moJubilant Pharmova Limited
Shwetank Tiwari
DIN 02413671
Company Secretary16 Jan 20188 yrs 10 moVanthys Pharmaceutical Development Private Limited
Benny Thomas
DIN 07241561
Director28 Mar 20188 yrs 7 moVanthys Pharmaceutical Development Private Limited
Shyamsundar Bang
DIN 00011327
Director28 Mar 20188 yrs 7 moVanthys Pharmaceutical Development Private Limited
Arun Seth
DIN 00204434
Director22 Oct 20188 yrs 1 moJubilant Pharmova Limited
Saravanakumar Dhakshinamoorthy
DIN 08448999
Additional Director15 May 20197 yrs 6 moVanthys Pharmaceutical Development Private Limited
Shirish Gundopant Belapure
DIN 02219458
Director07 Mar 20233 yrs 8 moJubilant Pharmova Limited
Shivpriya Nanda
DIN 01313356
Director01 Apr 20242 yrs 7 moJubilant Pharmova Limited
Harsh Mahajan
DIN 00824227
Director01 Apr 20242 yrs 7 moJubilant Pharmova Limited

People of Jubilant Pharmova

91 people are tracked at Jubilant Pharmova (47 in leadership, 44 in team); the tracked headcount is 165.

NameRoleGroup
Jaidev Rajpal
CEOLeadership
Apratim Bose
Head Digital - Pharmova & Site IT Head - RadiopharmaLeadership
Jagdish Mahajan
Senior Director - International Marketing (non Us)Leadership
Ashok Kumar Gupta
Deputy General Manager Supply ChainLeadership
Lt Col Kamaljeet Singh Pabla
Senior Director And Group Head - Adminstration, Corporate Services,security & VigilanceLeadership
Shailendra Chaudhari
Head- Manufacturing & Operational Excellence And Technical ServicesLeadership
Satyanarayana Potlacheruvu
Associate Director - CSVLeadership
Managing DirectorLeadership
Joint Managing DirectorLeadership
Chris Preti
Ceo - CdmoLeadership
Ashish Sinha
Vice President & SBU Head - Animal And Human Nutrition & Health SolutionsLeadership
Brian Enright
Senior Vice President, QualityLeadership
Gayatri Taragi
Global Head - RewardsLeadership
Piyush Agarwal
Vp, Finance | HEAD - Risk, Treasury & AssuranceLeadership
Jasdeep Singh Sood
Sr. Vice President & Head : Emerging Markets (global Formulation Business Excluding Usa)Leadership
Anupam Malhotra
Head (general Manager)- Technology TransferLeadership
Sukhpal Singh
GU Head (associate Vice President)Leadership
Vikas Gandhi
Associate Director ( Sales Head Latin America,middle East, Africa And India)Leadership
Manish Papnai
Associate Director Compensation & BenefitsLeadership
Ankush Raman Sharma
DirectorLeadership

71 more people are available in the full profile.

Premium access

Complete people profiles for Jubilant Pharmova

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

IPO & Listings of Jubilant Pharmova

Jubilant Pharmova is a publicly listed company on the NSE with ticker symbol JUBLPHARMA in India, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

  • IPO date16 Jun 2003
  • Listed onNSE: JUBLPHARMA
  • Listed entityJubilant Pharmova Limited
  • Exchange sectorHealth technology
  • ISININE700A01033
  • Share price₹938.90 (-0.38% on the day) · 2026-10-14
  • Market capitalisation₹15,019 Cr
  • Price to earnings42.3
  • EPS (diluted, trailing year)₹22.18
  • Dividend yield0.53%
  • Volume (last session)391,864

Financials of Jubilant Pharmova

Exchange-reported figures of Jubilant Pharmova Limited, the listed company behind Jubilant Pharmova (NSE: JUBLPHARMA).

Financial Highlights

FY 2025-26 · Consolidated
Revenue
₹8,280 Cr
+14.4% YoY
EBITDA
₹1,200 Cr
+2.3% YoY
Profit After Tax
₹436 Cr
+9.1% YoY
Net Worth
₹7,093 Cr
+13.4% YoY
Total Assets
₹13,048 Cr
+21.2% YoY
Total Debt
₹3,615 Cr
+32.4% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue8,2807,2346,7036,2826,1306,0995,976
Revenue growth+14.5%+7.9%+6.7%+2.5%+0.5%+2.1%-
EBITDA1,2001,1737327191,1461,3751,515
EBITDA margin+14.5%+16.2%+10.9%+11.5%+18.7%+22.6%+25.4%
Profit before tax61498117027.806301,1331,233
Net profit43640045.30(389)416856922
Net profit margin+5.3%+5.5%+0.7%-6.2%+6.8%+14.0%+15.4%
EPS (₹)25.2253.134.88(3.84)26.0052.5156.39
Balance sheet
Total assets13,04810,7629,7489,4318,6127,69210,572
Net worth7,0936,2555,4345,3995,3194,7415,604
Total debt3,6152,7313,6643,6773,1922,8304,808
Cash & bank1,2681,0899571,0149846711,400
Net working capital1,8851,7552,2862,3432,4331,9743,352
Cash flow
Cash from operations1,2271,0729716618381,7841,543
Cash from investing(1,143)512(596)(474)(323)(727)(267)
Cash from financing94.90(1,453)(432)(157)(32.60)(1,709)(1,050)
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue2,3702,2292,2902,1221,9661,9011,9291,822
Revenue growth (YoY)+20.5%+17.3%+18.7%+16.5%+12.2%+9.8%--
Other income14.4019.9023.7020.509.8012.0011.909.20
EBITDA240248326250336290342268
EBITDA margin+10.2%+11.2%+14.3%+11.8%+17.1%+15.4%+17.9%+14.8%
Depreciation13512711712110598.1095.2091.30
Interest58.4054.2056.5056.1050.2049.0052.7055.60
Profit before tax61.7086.4017693.40190154206130
Tax30.7030.0056.7037.6070.4051.9054.7029.80
Net profit31.0056.4011955.80120102151101
EPS (₹)1.973.567.523.527.576.479.686.36
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue2642317858107262,7103,140
Revenue growth+13.9%-70.5%-3.1%+11.6%-73.2%-13.7%-
EBITDA40.1037.7016.503.106.46427369
EBITDA margin+15.2%+16.3%+2.1%+0.4%+0.9%+15.8%+11.8%
Profit before tax72.5038.4041.7079.3084.72273299
Net profit70.8422.2032.3649.6580.47215326
Net profit margin+26.9%+9.6%+4.1%+6.1%+11.1%+7.9%+10.4%
EPS (₹)3.971.211.993.145.0513.4620.16
Balance sheet
Total assets2,3772,6822,7822,7842,6461,7914,687
Net worth2,3122,3182,3742,4142,4391,2822,607
Total debt52.703363803461835042,013
Cash & bank10.3012.6036.1011.0022.5340.33258
Net working capital(4.60)25733135427622.01987
Cash flow
Cash from operations93.60136143(65.10)(3.55)608317
Cash from investing34.00(2.30)(40.30)31.1093.10178(198)
Cash from financing(130)(157)(77.80)22.50(107)(782)(41.05)
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue68.5067.1070.3067.3066.4059.5060.7056.10
Revenue growth (YoY)+3.2%+12.8%+15.8%+20.0%+8.1%+11.8%--
Other income0.900.100.500.4042.402.4013.002.80
Total expenses56.8055.1064.5055.1054.6049.2049.8046.10
EBITDA11.7012.005.8012.2011.8010.3010.9010.00
EBITDA margin+17.1%+17.9%+8.3%+18.1%+17.8%+17.3%+18.0%+17.8%
Depreciation1.301.401.301.601.601.501.501.50
Interest1.000.900.900.902.503.003.103.30
Profit before tax10.309.804.1010.1050.108.2019.308.00
Tax2.702.50(53.10)3.5056.502.405.702.70

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 21 Nov 2026
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue2,3702,2292,2902,1221,9661,9011,9291,822
Revenue growth (YoY)+20.5%+17.3%+18.7%+16.5%+12.2%+9.8%--
Other income14.4019.9023.7020.509.8012.0011.909.20
EBITDA240248326250336290342268
EBITDA margin+10.2%+11.2%+14.3%+11.8%+17.1%+15.4%+17.9%+14.8%
Depreciation13512711712110598.1095.2091.30
Interest58.4054.2056.5056.1050.2049.0052.7055.60
Profit before tax61.7086.4017693.40190154206130
Tax30.7030.0056.7037.6070.4051.9054.7029.80
Net profit31.0056.4011955.80120102151101
EPS (₹)1.973.567.523.527.576.479.686.36
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue8,2807,2346,7036,2826,1306,0995,976
Revenue growth+14.5%+7.9%+6.7%+2.5%+0.5%+2.1%-
Other income66.0041692.8050.6011.29291258
Total expenses7,0796,0615,9715,5624,9844,7234,461
Employee cost2,7012,2682,2162,1662,0431,9231,843
EBITDA1,2001,1737327191,1461,3751,515
EBITDA margin+14.5%+16.2%+10.9%+11.5%+18.7%+22.6%+25.4%
Depreciation440369382554382349340
Interest212240272188145184200
Profit before tax61498117027.806301,1331,233
Tax21714497.8092.70217297335
Net profit43640045.30(389)416856922
Net profit margin+5.3%+5.5%+0.7%-6.2%+6.8%+14.0%+15.4%
EPS (₹)25.2253.134.88(3.84)26.0052.5156.39
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital15.8015.8015.8015.9015.9215.9215.93
Reserves & surplus7,0776,2395,4185,3835,3034,7265,588
Shareholders' funds (net worth)7,0936,2555,4345,3995,3194,7415,604
Minority interest2.80(16.30)(12.80)(7.50)(2.16)0.030.00
Secured loans54045649652326540.78999
Unsecured loans3,0742,2753,1683,1532,9272,7893,810
Total debt3,6152,7313,6643,6773,1922,8304,808
Total liabilities13,04810,7629,7489,4318,6127,69210,572
Assets
Gross block10,1677,8237,8697,3686,6926,0907,983
Net block6,9665,1765,0915,1834,8714,6096,340
Capital work in progress4,0403,6302,1031,5621,090897768
Investments61.4043.5042.2025623924169.36
Inventories1,2321,1291,2901,3801,2551,1291,845
Sundry debtors1,0708929169619288201,293
Cash & bank balances1,2681,0899571,0149846711,400
Loans & advances541468714406342332500
Total current assets4,1093,5773,8763,7623,5092,9525,038
Total current liabilities2,2241,8221,5901,4191,0769791,686
Net working capital1,8851,7552,2862,3432,4331,9743,352
Total assets13,04810,7629,7489,4318,6127,69210,572
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash1,0889561,0149845021,1541,005
Net cash from operating activities1,2271,0729716618381,7841,543
Net cash from investing activities(1,143)512(596)(474)(323)(727)(267)
Net cash from financing activities94.90(1,453)(432)(157)(32.60)(1,709)(1,050)
Net change in cash179132(57.50)30.10482(652)225
Closing cash1,2681,0899571,0149846711,400
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+14.5%+7.9%+6.7%+2.5%+0.5%+2.1%-
EBITDA growth+2.3%+60.3%+1.7%-37.2%-16.6%-9.2%-
PBT growth-37.4%+475.1%+513.3%-95.6%-44.4%-8.2%+36.5%
Net income growth+9.1%+782.1%+111.6%-193.5%-51.4%-7.1%-
Revenue CAGR (3Y)+9.6%+5.7%+3.2%+1.7%-12.4%-6.7%+0.7%
EBITDA CAGR (3Y)+18.6%+0.8%-19.0%-22.0%-7.7%-3.3%+4.0%
Profitability & leverage
Net income margin+4.8%+11.6%+1.1%-1.0%+6.7%+13.7%+15.0%
Return on capital employed+6.9%+8.4%+6.4%+3.1%+9.5%+11.9%+14.1%
Return on net worth+6.0%+6.8%+0.8%-7.3%+8.2%+16.6%+17.3%
Debt / equity0.480.550.680.640.600.740.93
Long-term debt / equity0.430.490.620.560.540.640.78
Interest cover27.8729.8777.80113.7819.0317.9416.99
Efficiency & per share
Fixed asset turnover0.920.920.880.890.960.870.80
Inventory turnover7.015.985.024.775.144.103.66
Debtors turnover8.448.017.146.657.015.774.66
EPS (₹)25.2253.134.88(3.84)26.0052.5156.39
Dividend per share (₹)5.005.005.005.005.005.005.00
Book value per share (₹)448.91395.88343.92339.58334.10297.85351.78
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue68.5067.1070.3067.3066.4059.5060.7056.10
Revenue growth (YoY)+3.2%+12.8%+15.8%+20.0%+8.1%+11.8%--
Other income0.900.100.500.4042.402.4013.002.80
Total expenses56.8055.1064.5055.1054.6049.2049.8046.10
EBITDA11.7012.005.8012.2011.8010.3010.9010.00
EBITDA margin+17.1%+17.9%+8.3%+18.1%+17.8%+17.3%+18.0%+17.8%
Depreciation1.301.401.301.601.601.501.501.50
Interest1.000.900.900.902.503.003.103.30
Profit before tax10.309.804.1010.1050.108.2019.308.00
Tax2.702.50(53.10)3.5056.502.405.702.70
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue2642317858107262,7103,140
Revenue growth+13.9%-70.5%-3.1%+11.6%-73.2%-13.7%-
Other income45.7020.2010313812647.88173
Total expenses2231947688077192,2822,771
Employee cost10492.10190167164221265
EBITDA40.1037.7016.503.106.46427369
EBITDA margin+15.2%+16.3%+2.1%+0.4%+0.9%+15.8%+11.8%
Depreciation6.006.6048.3043.2036.9199.97107
Interest7.3012.9029.9018.5010.99102136
Profit before tax72.5038.4041.7079.3084.72273299
Tax9.3019.2010.1029.404.2358.69(22.30)
Net profit70.8422.2032.3649.6580.47215326
Net profit margin+26.9%+9.6%+4.1%+6.1%+11.1%+7.9%+10.4%
EPS (₹)3.971.211.993.145.0513.4620.16
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital15.9015.9015.9015.9015.9315.9315.93
Reserves & surplus2,2962,3022,3592,3992,4231,2672,591
Shareholders' funds (net worth)2,3122,3182,3742,4142,4391,2822,607
Secured loans50.0021326122295.0095.00899
Unsecured loans2.7012311912387.524091,114
Total debt52.703363803461835042,013
Total liabilities2,3772,6822,7822,7842,6461,7914,687
Assets
Gross block1561,0369979478631492,288
Net block1166997116876371271,865
Capital work in progress11.5019.3037.0047.0035.260.3359.09
Investments2,1761,6571,6571,6571,6461,6461,764
Inventories0.002322513143230.00656
Sundry debtors23.802061941881310.00425
Cash & bank balances10.3012.6036.1011.0022.5340.33258
Loans & advances16.8032.9059.4065.7049.4025.92383
Total current assets50.9048454157952666.251,722
Total current liabilities55.5022721022525044.24735
Net working capital(4.60)25733135427622.01987
Total assets2,3772,6822,7822,7842,6461,7914,687
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash12.6036.1011.0022.5040.3535.6418.70
Net cash from operating activities93.60136143(65.10)(3.55)608317
Net cash from investing activities34.00(2.30)(40.30)31.1093.10178(198)
Net cash from financing activities(130)(157)(77.80)22.50(107)(782)(41.05)
Net change in cash(2.30)(23.50)25.10(11.50)(17.82)4.6978.00
Closing cash10.3012.6036.1011.0022.5340.33258
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+13.9%-70.5%-3.1%+11.6%-73.2%-13.7%-
EBITDA growth+6.4%+128.5%+432.3%-52.0%-98.5%+15.7%-
PBT growth+88.8%-7.9%-47.4%-6.4%-69.0%-8.6%+62.9%
Net income growth+219.1%-31.4%-34.8%-38.3%-62.5%-34.2%-
Revenue CAGR (3Y)-31.2%-31.7%-33.8%-36.3%-40.5%-6.4%+8.0%
EBITDA CAGR (3Y)+134.7%+80.0%-66.2%-79.7%-72.8%-7.5%+5.1%
Profitability & leverage
Net income margin+24.0%+8.3%+4.0%+6.2%+11.1%+7.9%+10.2%
Return on capital employed+1.8%+1.9%+2.6%+3.6%+4.3%+11.6%+9.9%
Return on net worth+3.1%+0.8%+1.3%+2.1%+4.3%+11.0%+13.0%
Debt / equity0.080.150.150.110.180.650.75
Long-term debt / equity0.050.100.100.080.160.460.44
Interest cover21.4141.48-94.03-46.13-36.0931.1252.02
Efficiency & per share
Fixed asset turnover0.440.230.810.891.432.221.53
Inventory turnover2.270.962.782.544.498.265.47
Debtors turnover2.291.164.105.0811.1112.746.93
EPS (₹)3.971.211.993.145.0513.4620.16
Dividend per share (₹)5.005.005.005.005.005.005.00
Book value per share (₹)145.43145.79149.34151.86153.1180.51163.67

Similar companies to Jubilant Pharmova

Jubilant Pharmova has 3 listed similar companies in our database, 2 of them funded. They include Akums, Jubilant Life Sciences and Nectar Lifesciences.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
akums.in2004Delhi, India$70M395
CDMO focusing on spectrum of dosage forms and therapeutic segments
jubl.com1978Noida, India
Company offering a suite of R&D and manufacturing services for small molecules and generics
neclife.com1995Chandigarh, India$46.85M175
Cephalosporin APIs and generic formulations are manufactured.
Premium access

Detailed similar companies of Jubilant Pharmova

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Web traffic of Jubilant Pharmova

The website of Jubilant Pharmova (jubilantpharmova.com) receives about 7K visits a month.

  • Monthly visits
    7K

    ▼ 16% vs previous month

Similar websites

Websites whose visitors overlap most with Jubilant Pharmova. Affinity shows how closely the audiences match.

WebsiteDomainAudience affinityMonthly visitsGlobal rankProfile
granulesindia.com
100%
14.1K#1,691,049View details
rakesh-jhunjhunwala.in
94%
#1,251,634View details
jubl.com
71%
48.5K#611,852View details
jubilantpharma.com
24%
7KView details
jubilantindustries.com
24%
1.9K#8,593,046View details
••••••••••••••••.com••%•.•M#•••••–
••••••••••••••••.com••%•.•M#•••••–
••••••••••••••••.com••%•.•M#•••••–
Premium access

All 8 similar websites and full traffic analytics for Jubilant Pharmova

The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.

  • 8 similar websites
  • Audience overlap
  • Engagement analytics
  • Traffic by brand

Verified entity values are shown only after access is granted.

Top companies in Biopharma Outsourcing & Drug Delivery

3 companies that operate in the same segment as Jubilant Pharmova (Biopharma Outsourcing & Drug Delivery) in India, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
Developer of integrated contract research development and manufacturing services
2007Bengaluru, Karnataka, IndiaUSD 35.74 MUSD 226.38 M2,062
Pharmaceutical and biotechnology company
2005Hyderabad, Telangana, IndiaUSD 229.73 MUSD 726.15 M548
India's leading healthcare products distribution platform
2018Mumbai, Maharashtra, IndiaUSD 59.67 MUSD 702.49 M557
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • ✓
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • ✓
    Full access to every database India & global coverage, advanced filters and rich profile details
  • ✓
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Jubilant Pharmova

JUBLPHARMA: Q2 CONS NET PROFIT 312M RUPEES VS 1.2B (YOY)
Exchange Update • 8 days ago
JUBLPHARMA: Q2 EBITDA 2.4B RUPEES VS 3.41B (YOY); Q2 EBITDA MARGIN 10.15% VS 17.36% (YOY)
Exchange Update • 8 days ago
JUBLPHARMA: Q2 REVENUE 23.7B RUPEES VS 19.66B (YOY)
Exchange Update • 8 days ago
JUBLPHARMA: Rs. 18.28 Crores NSE Block Trade; for ~ 200,560 Shares, at Rs. 911.60
Exchange Update • 1 month ago
Jubilant Pharmova: Board Agrees To Issue Up To ₹800 Crore In Non-Convertible Debentures Through Private Placement; Looking For Member Approval For Up To ₹2,500 Crore In Debt Securities Over The Next Year.
Exchange Update • 1 month ago
Jubilant Pharmova: Company Announces CAD 94.5 Million Investment to Increase Ruby-Fill® Production Capacity; Government of Canada to Provide CAD 23.8 Million in Support; Expansion Targets Growing Demand in Radiopharmaceuticals.
Exchange Update • 1 month ago
Jubilant Pharmova: Weighs Options To Raise Funds By Issuing Non-Convertible Debentures.
Exchange Update • 1 month ago
Premium access

Complete news archive for Jubilant Pharmova

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Jubilant Pharmova

Jubilant Pharmova was founded in 2020.

Jubilant Pharmova is headquartered in Amroha, India. It is registered at Amroha, Uttar Pradesh, India.

Jaidev Rajpal is the CEO of Jubilant Pharmova, as recorded in our data.

Jubilant Pharmova has 165 employees.

The primary company behind Jubilant Pharmova, Jubilant Pharmova Limited, reported revenue of ₹8,346 Cr for FY 2026, up 14% year on year.

Jubilant Pharmova was founded in 2020 in Amroha, India, within the pharmaceutical sector. Operations are centered on contract development and manufacturing services for solid, semi-solid, liquid, and injectable drug formulations. The company is headquartered in India, with its domain registered as jubilantpharmova.com. Leadership is provided by CEO Jaidev Rajpal, overseeing production activities for pharmaceutical clients.

Jubilant Pharmova's top competitors include Jubilant Life Sciences, Akums and Nectar Lifesciences.

Yes, Jubilant Pharmova is publicly traded on NSE under the ticker symbol JUBLPHARMA.

Jubilant Pharmova is associated with 2 legal entities: Jubilant Pharmova Limited, Vanthys Pharmaceutical Development Private Limited.

The legal entities of Jubilant Pharmova currently have 17 directors, including Nitin Garg, Benny Thomas, Saravanakumar Dhakshinamoorthy and others.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available